March 25, 2021Open Access

Camrelizumab Combined with Chemotherapy Followed by Camrelizumab plus Apatinib as First-line Therapy for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

Camrelizumab combined with CAPOX followed by camrelizumab plus apatinib demonstrated encouraging antitumor activity and manageable toxicity as first-line therapy for patients with advanced or metastatic G/GEJ adenocarcinoma.

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo

Cite This Study

Peng et al. (Thu,) studied this question.

synapsesocial.com/papers/69d89d71183921ebcaae2efb https://doi.org/https://doi.org/10.1158/1078-0432.ccr-20-4691

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 20122014 · 29,059 citations
2Simultaneous blockade of programmed death 1 and vascular endothelial growth factor receptor 2 (VEGFR2) induces synergistic anti-tumour effect <i>in vivo</i>2013 · 281 citations
3LBA6_PR Nivolumab (nivo) plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC)/esophageal adenocarcinoma (EAC): First results of the CheckMate 649 study2020 · 205 citations
4Simultaneous blockade of programmed death 1 and vascular endothelial growth factor receptor 2 (VEGFR2) induces synergistic anti-tumour effect in vivo.2013 · 24 citations
5CheckMate 649: A randomized, multicenter, open-label, phase III study of nivolumab (NIVO) + ipilimumab (IPI) or nivo + chemotherapy (CTX) versus CTX alone in patients with previously untreated advanced (Adv) gastric (G) or gastroesophageal junction (GEJ) cancer.2018 · 30 citations

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo